1. U.S. Food and Drug Administration. Accelerated approval. 2023. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval. Accessed 10 July 2023.
2. U.S. Food and Drug Administration CDER Accelerated Approval Program Database. 2023. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program. Accessed 10 July 2023.
3. Sachs RE, Donohue JM, Dusetzina SB. Accelerated approval—taking the FDA’s concerns seriously. N Engl J Med. 2022;387(3):199–201. https://doi.org/10.1056/NEJMp2204487.
4. U.S. Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. FDA; FDA. 2020. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy. Accessed 10 July 2023.
5. U.S. Food and Drug Administration. FDA Commissioner and Chief Scientist announce decision to withdraw approval of Makena. 2023. https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena. Accessed 10 July 2023.